Penumbra – 2026-01-15 - Increase Confidence 9/10

PEN – Increase in Days/Weeks

Penumbra reported preliminary Q4 2025 revenue growth of 21–22% YoY, signaling sustained demand for its thrombectomy and neurovascular devices. This momentum is amplified by Boston Scientific’s $14.5 billion acquisition offer at $374 per share, representing a 6.6% premium to the current price.

Why This Matters

The combination of robust organic growth—especially 25% ex-China—and a strategic acquisition by a major medtech player creates a powerful near-term catalyst. With the deal priced above the 52-week high and strong analyst backing, arbitrage and momentum flows are likely to push shares higher in the weeks leading to shareholder and regulatory approval.

Key Insights

• Revenue Growth: Q4 2025 revenue up 21–22% YoY, full-year 2025 revenue ~$1.40 billion (+17% YoY, 25% ex-China)
• News Impact: Boston Scientific acquisition at $374/share (6.6% above current price) creates a clear upside target
• Risk/Offset: Deal completion subject to regulatory approval; minor insider selling observed but not material

Practical Implications

• Bull Case: Acquisition closes as expected → stock converges to $374 by Q2 2026 (+6.6% in weeks)
• Bear Case: Regulatory delays or antitrust concerns could stall deal, capping upside near current levels
• Confidence: 9/10 – High visibility on deal terms and strong financial performance support near-term move

Prediction: increase

Reference:

• https://www.benzinga.com/m-a/26/01/49933167/boston-scientific-acquires-penumbra-in-14-5-billion-bet-to-dominate-thrombectomy
• https://www.finanznachrichten.de/nachrichten-2026-01/67444005-penumbra-inc-provides-preliminary-update-on-fourth-quarter-and-full-year-2025-financial-results-008.htm
• https://finance.yahoo.com/news/director-stock-sale-mmae-optimism-191517799.html